Trial Profile
Phase 2 Study of VAL-083 Treatment for MGMT Unmethylated Bevacizumab-naive Glioblastoma in the Adjuvant or Recurrent Setting
Status:
Suspended
Phase of Trial:
Phase II
Latest Information Update: 24 Nov 2023
Price :
$35
*
At a glance
- Drugs Dianhydrogalactitol (Primary)
- Indications Glioblastoma
- Focus Therapeutic Use
- Acronyms MDACC
- Sponsors Del Mar Pharmaceuticals; Kintara Therapeutics
- 20 Nov 2023 Planned End Date changed from 31 Dec 2022 to 30 Mar 2024.
- 20 Nov 2023 Planned primary completion date changed from 30 Oct 2022 to 30 Dec 2023.
- 31 Oct 2023 Status changed from active, no longer recruiting to suspended, according to Kintara Therapeutics media release.